Thromboembolic events associated with novel therapies in patients with multiple myeloma: consensus statement of the IMF Nurse Leadership Board.
Patients with myeloma are at risk for serious and life-threatening thromboembolic events because of their disease, individual risk factors, and antimyeloma or other medications. The International Myeloma Foundation's Nurse Leadership Board developed this consensus statement for assessment and prevention of thromboembolic events. Prophylactic measures are categorized as mechanical, regimen related, and antithrombotic drug, based on individual and myeloma-related risk factors. Aspirin is suggested for patients with no or one risk factor, low-molecular-weight heparin or full-dose warfarin for patients with two or more risk factors, and low-molecular-weight heparin or full-dose warfarin for all patients with therapy-related risks, including high-dose dexamethasone, doxorubicin, or multiagent chemotherapy.
Rome
Sandra
S
Cedars-Sinai Medical Center, Los Angeles, CA, USA. romes@cshs.org
Doss
Deborah
D
Miller
Kena
K
Westphal
Jeanne
J
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D032921:Consensus; D006801:Humans; D007857:Leadership; D009101:Multiple Myeloma / Q000188:drug therapy*; D010353:Patient Education as Topic; D012307:Risk Factors; D012956:Societies, Nursing; D013923:Thromboembolism / Q000139:chemically induced* / Q000517:prevention & control / Q000628:therapy
D000970:Antineoplastic Agents